Apollomics

Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies.

Founded 2015

Foster City, United States 26 employees Post-IPO Equity Total: $262.60M Biotechnology, Health Care +1

Apollomics is a biopharmaceutical company with a clear mission to discover and develop mono- and combination cancer therapies. Established in 2016, Apollomics has made strategic moves to operate in both the U.S. and China, aiming to harness synergies by collaborating with biotechnology companies in both the East and the West. Under the guidance of a seasoned management team, Apollomics has constructed a robust pipeline consisting of 10 drug candidates across 12 programs, 5 of which are undergoing clinical trials. These candidates are grouped based on their mechanisms of action, falling into three categories: "tumor inhibitors," "anti-cancer enhancers," and "immuno-oncology drugs." This diverse approach enables the development of synergistic combination therapies targeted at addressing unmet needs in cancer treatment. Moreover, the company has secured a $23.65M Post-IPO Equity investment on 30 March 2023. With a focus on biotechnology, healthcare, and pharmaceuticals industries, Apollomics is poised to make significant strides in the field of oncology. To stay updated on Apollomics’ latest advancements, visit their website at www.apollomicsinc.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$23.65M	-		30 Mar 2023
Series C	$124.20M	2	WR Hambrecht + Co, Ping An Capital	05 Nov 2020
Series B	$100.00M	7	OrbiMed, K2VC +5	08 Jan 2019
Series A	$9.75M	1	OrbiMed	29 Aug 2016
Seed Round	$5.00M	-		01 Jan 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$23.65M

30 Mar 2023

Series C

$124.20M

WR Hambrecht + Co, Ping An Capital

05 Nov 2020

Series B

$100.00M

OrbiMed, K2VC +5

08 Jan 2019

Series A

$9.75M

OrbiMed

29 Aug 2016

Seed Round

$5.00M

01 Jan 2016

FAQ About Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies.

Apollomics was founded in 2015.

Apollomics is headquartered in Foster City, United States.

Apollomics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical company, oncology therapies, combination therapies and cancer treatment.

Apollomics has approximately 26 employees.

Apollomics has completed 5 funding rounds, raising a total of $262.60M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Apollomics include Prescient Therapeutics, Surface Oncology Inc., ImmunoCellular Therapeutics Ltd, Curis, Genprex, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Apollomics and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Apollomics

Funding Rounds & Investors (5)

Apollomics Alternatives & Competitors

FAQ About Apollomics